New England Journal of Medicine· 2016Q1
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
- 1,980citations
- Q1SCImago
- 2016year
Short summary
Ocrelizumab significantly reduced disease activity in relapsing multiple sclerosis (MS) patients over 96 weeks, showing 94-95% fewer MRI lesions compared to interferon beta-1a.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Pathology and Forensic Medicine
Pathology and Forensic MedicineMedicine